President Donald Trump is under pressure to decide how widely available anti-obesity drugs should be and whether Medicare ...

The Trump Administration has promised not to cut Medicare and Medicaid benefits but that doesn’t mean it’s been leaving things alone there. Here’s what’s been happening at CMS.

The Trump administration has decided against implementing a proposal for Medicare and Medicaid to cover weight loss drugs, ...

The decision counters a proposal by the Biden Administration to reimburse beneficiaries for the weight-loss medications.

Independence Health Group, the parent company of Independence Blue Cross, spent $500 million last year to provide ...

Expanding Medicare coverage for glucagon-like peptide 1 (GLP-1) receptor agonists could significantly reduce obesity-related ...

BUFFALO, N.Y. — In January, Nicole Albanese, PharmD, clinical associate professor of pharmacy practice in the University at ...

Pa., said Mounjaro changed his life with 'significant' health benefits. He's calling for widespread access to GLP-1 ...

The Centers for Medicare & Medicaid Services on Friday rejected a Biden administration proposal to expand Medicare coverage of weight-loss drugs such as Eli Lilly's Zepbound and Novo Nordisk's ...

Mochi Health, one of those implicated, is one of the largest telehealth providers of compounded GLP-1RAs. Eli Lilly maintains ...

Donald Trump, at 78, is aggressively pursuing his second term, marked by significant policy changes and a noticeable physical ...

Jamie Mafdali of South Florida was hit with a cancer double-whammy three years ago. Shortly after her mother began treatment ...